Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -46.36% is 43% above its 1-year average of -81.42%, around the middle of its 1-year range (-199.50%–36.66%).
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-46.36%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$65.40M
EBITDA Margin
-0.14%
TTM Avg
-3.20%
3Y Avg
-62.68%
5Y Avg
-125.61%
Market Cap
$64.28M
EBITDA Margin
-334.74%
TTM Avg
-191.68%
3Y Avg
-191.68%
5Y Avg
-191.68%
Market Cap
$63.18M
EBITDA Margin
-16170.91%
TTM Avg
-8243.87%
3Y Avg
-8243.87%
5Y Avg
-8243.87%
Market Cap
$64.31M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$68.07M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$60.02M
EBITDA Margin
-270.28%
TTM Avg
-442.93%
3Y Avg
-1031.00%
5Y Avg
-861.19%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $64.06M | -46.36% | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $65.40M | -0.14% | -3.20% | -62.68% | -125.61% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.28M | -334.74% | -191.68% | -191.68% | -191.68% |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.84% | -6.43% | -1.20% | -7.11% |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.18M | -16170.91% | -8243.87% | -8243.87% | -8243.87% |
| PDS Biotechnology Corporation (PDSB)vs › | $64.31M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $66.18M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.07M | -103.63% | -143.63% | -176.25% | -194.05% |
| Adicet Bio, Inc. (ACET)vs › | $60.02M | -270.28% | -442.93% | -1031.00% | -861.19% |
| iBio, Inc. (IBIO)vs › | $68.81M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
Gross Margin
32.1%
EBITDA Margin
-46.4%
Operating Margin
-69.6%
Net Margin
-41.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-03-31 | 36.66% |
| 2022-12-31 | -199.50% |
